Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-2-activated natural killer cells
- Development stage
- Unknown
- Lead developer
- Institut Paoli-Calmettes
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Interleukin-2-activated natural killer cells (IL-2 NK) are an adoptive cellular immunotherapy consisting of donor-derived natural killer (NK) cells that are purified and activated ex vivo with high doses of interleukin-2 (IL-2) prior to infusion. This activation process enhances the expression of activating receptors such as NKp44, CD69, and TRAIL, and significantly increases the cells' cytotoxic capacity and cytokine production (e.g., IFN-gamma). In the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT), these cells are administered prophylactically to bolster the graft-versus-tumor (GVT) effect and clear residual disease while minimizing the risk of graft-versus-host disease (GVHD), which is a common complication of conventional donor lymphocyte infusions.
- Other names
- donor-derived IL-2-activated NK cellsIL-2 activated NK cellsIL2 activated NK cellsIL 2 activated NK cells
02
Targets
NKG2DL (NKG2D ligand family)
Beyond the preview
Go deeper on interleukin-2-activated natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-2-activated natural killer cells.